STAT

MAY 23, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning. Wall Street had a big reaction to H5N1 bird flu news yesterday. Was it warranted? We’ll discuss that today. Read the rest…

Vaccines 334

Vaccines Drug Pricing Drug Development 334

STAT

FEBRUARY 1, 2024

Biotech can’t shake the Fed The XBI, a closely watched index of biotech stocks, turned red for the year yesterday, and not because of a clinical disappointment, a drug pricing scandal, or an M&A rumor that came to nothing. In 2024, as in 2023, the industry’s fate seems inextricable from interest rates.

Drug Pricing 319

Drug Pricing Vaccines Communication Drug Development 319

STAT

NOVEMBER 3, 2023

There’s potential that a stem cell infusion from kidney donors might help prevent organ rejection — allowing patients to perhaps wean from immunosuppressive drugs. Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox.

Vaccines 291

Vaccines Drug Pricing Drug Development 291

STAT

JUNE 10, 2024

Lots on vaccines this morning: Moderna says its combination shot for Covid and flu works well, and might help improve uptake in the broader population. And the FDA just cleared GSK’s RSV vaccine for younger at-risk adults. Want to stay on top of the science and politics driving biotech today?  Read the rest…

Vaccines 290

Vaccines Drug Pricing Drug Development 290

STAT

AUGUST 15, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning. Big news this morning, so let’s get straight into it. Read the rest…

Vaccines 294

Vaccines Drug Pricing Drug Development 294

STAT

MARCH 25, 2024

We also examine how Covid-19 vaccine makers are faring today, and more. Today, we discuss the implications of the Supreme Court’s forthcoming mifepristone evaluation on the FDA and the biopharma industry. Read the rest…

Vaccines 280

Vaccines Drug Pricing Drug Development 280

STAT

FEBRUARY 13, 2024

Today, some amazing intel on Merck’s Ebola vaccine: Turns out, it can reduce risk of death, even after a person has been infected. Also, investors bet on another obesity drug — this time from BioAge, which is combining Zepbound with a pill that keeps muscle wasting at bay. It’s Meghana.

Vaccines 263

Vaccines Drug Pricing Drug Development 263

STAT

JANUARY 16, 2024

Today, we talk a lot about regulatory policy — for flu vaccines and for physicians.   Sign up  to get our biotech newsletter in your inbox. Hope you had a restful and reflective long weekend.

Vaccines 263

Vaccines Drug Pricing Drug Development 263

STAT

FEBRUARY 22, 2024

Damian here with an update on the plight of the  other  Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom. Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, all.

Vaccines 269

Vaccines Drug Pricing Drug Development 269

STAT

DECEMBER 8, 2023

Today, we talk about the much-awaited CRISPR-based drug Casgevy, discuss the new Gavi initiative that plans to dramatically ramp up vaccine manufacturing in Africa, and more.   Sign up  to get our biotech newsletter in your inbox. Have a nice weekend! Read the rest…

Vaccines 245

Vaccines Drug Pricing Drug Development 245

STAT

NOVEMBER 13, 2023

We also learn about a new initiative to try and prevent gonorrhea spread with a meningitis vaccine. Lots of news on the cardiovascular front this morning: We discuss Novo Nordisk’s plans in heart disease, and Verve’s gene editing therapy for familial hypercholesterolemia. Read the rest…

Vaccines 261

Vaccines Drug Pricing Drug Development 261

STAT

JUNE 21, 2024

Enjoy, and see you soon… In a surprise move, Doctors Without Borders is closing down its access-to-medicines campaign, which has been credited with ensuring needed drugs and vaccines have been made available to countless patients in low-income countries around the world , STAT reports.

Vaccines 258

Vaccines Drug Pricing Drug Development 258

STAT

MAY 20, 2024

Today, we talk about how Bernie Sanders might be hitting a wall with the drug industry, see a glimmer of potential for HIV vaccines, and introduce a new Monday fundraising feature.   Sign up  to get our biotech newsletter in your inbox. Read the rest…

Vaccines 224

Vaccines Drug Pricing Drug Development 224

STAT

JUNE 4, 2023

Since then, a global pandemic showcased the industry’s prowess in rushing out lifesaving vaccines — elevating scientists to the status of saviors, at least for a fleeting moment. But complaints about steep prices for drugs have grown louder, sparking a backlash in Washington, D.C.,

Vaccines 252

Vaccines Drug Pricing Drug Development 252

STAT

DECEMBER 13, 2024

Although research and development funding for tuberculosis reached new heights last year, the total fell substantially short of goals set by the United Nations and most of the increase came from just two organizations, according to a new report.

Pharmaceutical Companies 141

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Pricing 141

STAT

APRIL 12, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with what is my final edition of The Readout on my last day at STAT.

Drug Pricing 274

Drug Pricing Drug Development Vaccines 274

STAT

MAY 22, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning. About a month ago, when I first started writing this newsletter, I shared the devastating news that the famed rat hole here in Chicago  was being removed.

Drug Pricing 271

Drug Pricing Drug Development Vaccines 271

STAT

JUNE 5, 2024

We’ve got a dramatic vote on psychedelic therapy, record drug shortages, bad (maybe?) Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning. Jason Mast here filling in for Elaine. news for Biomarin, and a new kind of PrEP.

Drug Pricing 269

Drug Pricing Drug Development Vaccines 269

Pharmaceutical Technology

DECEMBER 27, 2022

Reynald Castaneda wrote about the affected clinical trial ecosystems in both countries , while Fiona Barry and Manasi analysed the impact of the war on the supply of the Russian Covid-19 vaccine Sputnik V to the rest of the world. Tracking drug development.

Vaccines 122

Vaccines Drug Development Drug Pricing 122

STAT

JUNE 3, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning! It’s an ASCO-full newsletter today (and be sure to peruse the More Reads for more reads) but there’s so much more this week.

Drug Pricing 261

Drug Pricing Drug Development Vaccines 261

STAT

APRIL 11, 2024

Damian here with a look at a biotech deal with a lengthy backstory, the tyranny of gas prices, and the latest shakeup at BIO. Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Read the rest…

Drug Pricing 260

Drug Pricing Drug Development Vaccines 260

STAT

FEBRUARY 29, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with an explanation of the latest trend in biotech financing, a big idea in oncology, and Novo Nordisk’s plans to make Wegovy obsolete. Read the rest…

Drug Pricing 259

Drug Pricing Drug Development Vaccines 259

pharmaphorum

AUGUST 27, 2020

Regulatory pressures, lengthy drug development times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion. The first is that the development of vaccines is utilising cutting edge technologies.

Vaccines 122

Vaccines Drug Pricing Compounding Immunity 122

STAT

FEBRUARY 26, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a look at some renewed interest in a yesteryear biotech craze, news of an FDA flex, and a dive into the science of vaccinology. Read the rest…

Drug Pricing 259

Drug Pricing Drug Development Vaccines 259

STAT

MAY 17, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Asking again! Could you tell us what you think of The Readout? Fill out this  survey ! Read the rest…

Drug Pricing 239

Drug Pricing Drug Development Vaccines 239

STAT

DECEMBER 7, 2023

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with another multibillion-dollar deal, a word on the future of Sanofi, and a setback in one of medicine’s longest-running quests. Read the rest…

Drug Pricing 251

Drug Pricing Drug Development Vaccines 251

STAT

DECEMBER 22, 2023

Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter  here.

HIPAA 245

HIPAA Drug Pricing Drug Development Hospitals 245

STAT

NOVEMBER 21, 2023

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a look at an ambitious genomics startup, some cautious optimism on Wall Street, and a rough day for an American in Germany. Read the rest…

Drug Pricing 211

Drug Pricing Drug Development Vaccines 211

STAT

OCTOBER 6, 2023

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Today, we discuss why an advisory committee was not thrilled with Amgen’s data for Lumakras, and Neurocrine Biosciences has a potential blockbuster up its sleeve.

Drug Pricing 214

Drug Pricing Drug Development Vaccines 214

STAT

JUNE 18, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning! Elaine Chen is away, so I’m here in her stead. Take it slow out there, Northeast-ers, the outside temps are about to hit “wicked hot.” ” Read the rest…

Drug Pricing 154

Drug Pricing Drug Development Vaccines 154

European Pharmaceutical Review

DECEMBER 26, 2023

Production cost is currently a fundamental concern for many gene therapy developers, particularly given that some treatments cost millions of dollars per single dose (eg, $3.5 Single-use bioprocessing technologies enabling more rapid vaccines production [Internet]. million for Hemgenix [AAV5-hFIX-Padua]). Trends in Biotechnology.

Drug Pricing 98

Drug Pricing Packaging Vaccines Drug Development 98

PharmaShots

MAY 9, 2023

Social Factors Generation Health: This aspect is crucial as it corresponds to the layouts of drug development requirements based on the patient population of geography. Compared to the younger generation, the geriatric population requires more drugs.

Pharmaceutical Companies 56

Pharmaceutical Companies Pharmaceutical Companies Drug Development Drug Pricing 56

Pharmaceutical Technology

SEPTEMBER 26, 2022

GlobalData’s Contract Service Provider database shows that Novartis has 25 manufacturing sites in the US, Europe and China, including five API biologics (cell, gene, vaccine and virus) facilities in the US, France and Switzerland. These highlight the parent company’s focus on innovative and high-value drug development.

Biosimilars 64

Biosimilars Drug Development Vaccines Dosage 64

STAT

DECEMBER 9, 2024

President-elect Trump’s pick to run the Department of Health and Human Services , has lambasted the pharmaceutical industry and spread discredited ideas about vaccines.

Vaccines 346

Vaccines Drug Pricing Drug Development 346

STAT

OCTOBER 30, 2024

This story first appeared in The Readout newsletter.    Sign up for The Readout  and receive STAT’s award-winning biotech news delivered straight to your inbox.    Good morning. It’s a very busy and spooky Halloween eve today — several companies had big misses in earnings reported this morning.

Vaccines 261

Vaccines Drug Pricing Drug Development 261

Safe Biologics

SEPTEMBER 11, 2023

September 11, 2023 The Centers for Medicare & Medicaid Services (CMS) recently announced the first 10 drugs selected under its Medicare drug price “negotiation” plan, authorized by the Inflation Reduction Act (IRA) signed in to law last year. 1] 90% of new cancer drugs are available in the U.S.

Drug Pricing 150

Drug Pricing Biosimilars Vaccines Drug Development 150

STAT

NOVEMBER 8, 2024

have on vaccines in the U.S.? ’s vaccine views could shape policy President-elect Trump’s decision to entrust noted vaccine skeptic Robert F. One of particular import: What impact will his relationship with Robert F. Kennedy Jr. We have a look at that question today, discuss another U.S. How RFK Jr.’s

Vaccines 272

Vaccines Immunity Immunization Drug Pricing 272